The FDA has approved osimertinib as a first-line treatment for patients with non–small cell lung cancer whose tumors harbor EGFR mutations (exon 19 deletions or exon 21 L858R substitution mutations).
Original Article: FDA Approves Frontline Osimertinib for NSCLC